Product Adoption and Decision-Making

Supporting a Ministry of Health's decision to incorporate products into national guidelines

To guide the adoption of and decisions around new products, programs should work collaboratively with the Ministry of Health (MoH), implementing partners, and community groups. 

Product Adoption and Decision-Making Checklist

Evaluate the benefits and considerations of new products using the five lenses approach (outlined in the Product Adoption and Decision-Making Chapter)


Gather key information on the new product to build a case for its adoption and introduction (examples and samples included in resources section below) 

Build consensus on product adoption by engaging key stakeholders and decision makers utilizing existing forums such as technical working groups (TWG) 

Conduct a guidelines analysis and costing evaluation (e.g. using the WHO Guidelines Costing Tool)

Update national treatment guidelines based on new product decisions

Use the links below to download the entire HIV New Product Introduction Guide or the Product Adoption and Decision-Making chapter only
HIV New Product Introduction Guide
Product Adoption and Decision-Making Chapter

Product Adoption and Decision-Making Tools and Resources

In preparing for national discussions on product adoption, sufficient information on the new product should be compiled. This section outlines critical resources and tools that should be assembled and developed for sharing with key stakeholders during the technical engagement processes.

Treat all regimen spread for optimized regimen with proactive 2018 switch to TLE400
Annual Costs of Adults on Treatment for Baseline vs Test and Treat
Estimated number of adults on treatment
Cost PPPY for baseline vs test and treat
proactive switch in 2018 to DTG and TLE400
Treat all ATVr Scale Up
Total 5 Years Costs by Type of Cost

Featured Tool: WHO Guidelines Costing Tool

A Microsoft Excel-based tool, the CHAI WHO Guidelines Costing Tool helps programs make decisions about how and when to adopt WHO guidelines, including product phase-in strategies. Additionally, the tool provides countries with a better understanding of the costs of implementation, in addition to patient scale-up. The use of the tool is facilitated by trained CHAI staff and allows program managers to assess and compare different scenarios to answer policy questions for adults, adolescent, and pediatric guidelines. Outputs of this tool include: Costs of ARV drugs, lab commodities, and facility-level human resources. To learn more about the WHO Costing Tool, please reach out to

Product Profiles and Clinical Memos

Detailed analyses of the comparative advantages, including clinical efficacy, patient convenience, cost, availability, and simplicity for program, of the new product against those already available in country.

International Guidance

Consolidated international recommendations and guidance regarding new ARVs should be presented during key stakeholder forums (e.g TWGs, task force meetings, etc.). Countries should consider WHO recommendations for first- and second-line ARV treatment as they make decisions for treatment options.

Please reload


Market Intelligence: ARV Market Reports

Information on the latest developments and global outlook for the ARV marketplace and product pipeline, such as the CHAI ARV Market Report, an annual report developed by CHAI's HIV Market Intelligence Team.


Clinical Studies

Collect detailed information on any clinical trials or studies that were conducted on new ARVs, including full details of the studies, findings, and recommendations.  Specific information from the studies could include clinical efficacy, pharmacokinetic (PK) studies, toxicity profiles, and adverse events. Identify studies conducted in similar settings (e.g. Sub-Saharan Africa for Zimbabwe or South East Asia for Cambodia, for example).

Please reload

Featured Resource: New Product Development Timelines

Having a clear view of upcoming regulatory submissions allows countries to monitor dossier submissions to NDRAs and plan introduction based on expected product availability.  This resource shows the latest understanding of targeted regulatory filings for key ARVs. Please note that these timelines  are very dynamic and can change from month-to-month. This resource will be updated as information of timelines changes. Another resource for reference is a slide deck on "Drug Development 101" that provides a high-level overview of the drug development process:

Last Updated: August 2017